◆英語タイトル:Simcere Pharmaceutical Group - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013625
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月28日
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Simcere Pharmaceutical Group (Simcere) is a drug discovery company that manufactures and supplies branded generic and prescription pharmaceutical products. The company offers products in therapeutic areas including anti-tumor, central nervous, anti-infection, cardiovascular, skeletal muscle, and others. Its products include recombinant human endostatin injection, nedaplatin for injection, palonosetron hydrochloride injection, fluorouracil implants and lyvamlodipine besylate tablets, among others. Simcere’s products are used for the treatment of oncology, neurology, infectious diseases, anti-inflammation and cardiovascular disease. The company conducts research and development to develop new drugs. It partners with pharma companies to develop novel anti-VEGF humanized monoclonal antibody. Simcere is headquartered in Nanjing, China.
Simcere Pharmaceutical Group – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Simcere Pharmaceutical Group, Medical Devices Deals, 2011 to YTD 2017 10
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Amgen and Simcere Pharma Enter into Co-Development Agreement 12
Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For Orencia 13
Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For BMS-795311 15
Simcere Pharma Enters Into Co-Development Agreement With Suzhou NeuPharma 16
Simcere Pharma Enters Into Co-Development Agreement With Nanjing Medical University 17
Equity Offering 18
Simcere Pharma May Raise up to USD128.9 Million in Public Offering of Shares 18
Acquisition 19
Jinsheng Ren And Assure Ahead Investments Completes Acquisition Of Simcere Pharma For US$517 Million In Going Private Transaction 19
Zhuhai Rongding To Acquire Jilin Boda Pharma From Simcere Pharma For US$65 Million 21
Devont Asset Management To Acquire 35% Stake In Shanghai Celgen From Simcere Pharma For US$48 Million 22
Simcere Pharmaceutical Group – Key Competitors 23
Simcere Pharmaceutical Group – Key Employees 24
Simcere Pharmaceutical Group – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 27
Corporate Communications 27
Aug 02, 2016: Simcere Pharma announced appointment of D.r Hua Mu as Chief Officer of Science and President on Research and Development 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28
List of Tables
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Key Facts 2
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Simcere Pharmaceutical Group, Deals By Therapy Area, 2011 to YTD 2017 8
Simcere Pharmaceutical Group, Medical Devices Deals, 2011 to YTD 2017 10
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Amgen and Simcere Pharma Enter into Co-Development Agreement 12
Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For Orencia 13
Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For BMS-795311 15
Simcere Pharma Enters Into Co-Development Agreement With Suzhou NeuPharma 16
Simcere Pharma Enters Into Co-Development Agreement With Nanjing Medical University 17
Simcere Pharma May Raise up to USD128.9 Million in Public Offering of Shares 18
Jinsheng Ren And Assure Ahead Investments Completes Acquisition Of Simcere Pharma For US$517 Million In Going Private Transaction 19
Zhuhai Rongding To Acquire Jilin Boda Pharma From Simcere Pharma For US$65 Million 21
Devont Asset Management To Acquire 35% Stake In Shanghai Celgen From Simcere Pharma For US$48 Million 22
Simcere Pharmaceutical Group, Key Competitors 23
Simcere Pharmaceutical Group, Key Employees 24
Simcere Pharmaceutical Group, Subsidiaries 25